Patents by Inventor Hans Vallberg

Hans Vallberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7579366
    Abstract: The invention relates to epothilone analog represented by the formula I wherein (i) R2 is absent or oxygen; “a” can be either a single or double bond; “b” can be either absent or a single bond; and “c” can be either absent or a single bond, with the proviso that if R2 is oxygen then “b” and “c” are both a single bond and “a” is a single bond; if R2 is absent then “b” and “c” are absent and “a” is a double bond; and if “a” is a double bond, then R2, “b” and “c” are absent; R3 is a radical selected from the group consisting of hydrogen; lower alkyl; —CH?CH2; —C?CH; —CH2F; —CH2Cl; —CH2—OH; —CH2—O—(C1-C6-alkyl); and —CH2—S—(C1-C6-alkyl); R4 and R5 are independently selected from hydrogen, methyl or a protecting group; and R1 is as defined in the specification, or a salt of a compound of the formula I where a salt-forming group is present. A further aspect of the invention is related to the synthesis of epothilone E.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: August 25, 2009
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, Nigel Paul King, Maurice Raymond Verschoyle Finlay, Yun He, Frank Roschangar, Dionisios Vourloumis, Hans Vallberg, Antony Bigot
  • Patent number: 7173137
    Abstract: Epothilone A, epothilone B, analogs of epothilone and libraries of epothilone analogs are synthesized. Epothilone A and B are known anticancers agents that derive their anticancer activity by the prevention of mitosis through the induction and stabilization of microtubulin assembly. The analogs of epothilone are novel. Several of the analogs are demonstrated to have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: February 6, 2007
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, Yun He, Sacha Ninkovic, Joaquin Pastor, Frank Roschangar, Francisco Sarabia, Hans Vallberg, Dionisios Vourloumis, Nicolas Winssinger, Zhen Yang, Nigel Paul King, Maurice Raymond Verschoyle Finlay
  • Publication number: 20040127432
    Abstract: Epothilone A, epothilone B, analogs of epothilone and libraries of epothilone analogs are synthesized. Epothilone A and B are known anticancers agents that derive their anticancer activity by the prevention of mitosis through the induction and stabilization of microtubulin assembly. The analogs of epothilone are novel. Several of the analogs are demonstrated to have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules.
    Type: Application
    Filed: December 9, 2003
    Publication date: July 1, 2004
    Applicant: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, Yun He, Sacha Ninkovic, Joaquin Pastor, Frank Roschangar, Francisco Sarabia, Hans Vallberg, Dionisios Vourloumis, Nicolas Winssinger, Zhen Yang, Nigel Paul King, M. Ray Finlay
  • Patent number: 6660758
    Abstract: Epothilone A, epothilone B, analogs of epothilone and libraries of epothilone analogs are synthesized. Epothilone A and B are known anticancers agents that derive their anticancer activity by the prevention of mitosis through the induction and stabilization of microtubule assembly. The analogs of epothilone are novel. Several of the analogs are demonstrated to have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: December 9, 2003
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, Yun He, Sacha Ninkovic, Joaquin Pastor, Frank Roschangar, Francisco Sarabia, Hans Vallberg, Dionisios Vourloumis, Nicolas Winssinger, Zhen Yang, Nigel Paul King, M. Ray Finlay
  • Publication number: 20030203938
    Abstract: The invention relates to epothilone analog represented by the formula I 1
    Type: Application
    Filed: March 11, 2003
    Publication date: October 30, 2003
    Applicant: The Scripps Research Institute
    Inventors: Kyriacos Costa Nicolaou, Nigel Paul King, Maurice Raymond Verschoyle Finlay, Yun He, Frank Roschangar, Dionisios Vourloumis, Hans Vallberg, Antony Bigot
  • Patent number: 6531497
    Abstract: The invention relates to epothilone analog represented by formula (I) wherein (i) R2 is absent or oxygen; “a” can be either a single or double bond; “b” can be either absent or a single bond; and “c” can be either absent or a single bond, with the proviso that if R2 is oxygen then “b” and “c” are both a single bond and “a” is a single bond; if R2 is absent then “b” and “c” are absent and “a” is a double bond; and if “a” is a double bond, then R2, “b” and “c” are absent; R3 is a radical selected from the group consisting of hydrogen; lower alkyl; —CH═CH2; —C≡CH; —CH2F; —CH2Cl; —CH2—OH; —CH2—O—(C1-C6-alkyl); and —CH2—S—(C1-C6-alkyl); R4 and R5 are independently selected from hydrogen, methyl or a protecting group; and R1 is as defined in the specification, or a salt of a compound of formu
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: March 11, 2003
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos Costa Nicolaou, Nigel Paul King, Maruice Raymond Verschoyle Finlay, Yun He, Frank Roschangar, Dionisios Vourloumis, Hans Vallberg, Antony Bigot
  • Patent number: 6465466
    Abstract: Use of compounds of the formula I for preparing a medicament for protecting DNA in the initial phase and/or the promoting phase of carcinogenesis and for preventing oxidative stress in patients with diseases related to free radicals are described.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: October 15, 2002
    Inventors: Jan Bergman, Lennart Möller, Hans Vallberg
  • Patent number: 6441186
    Abstract: Epothilone A, epothilone B, analogs of epothilone and libraries of epothilone analogs are synthesized. Epothilone A and B are known anticancer agents that derive their anticancer activity by the prevention of mitosis through the induction and stabilization of microtubulin assembly. The analogs of epothilone are novel. Several of the anlogs are demonstrated to have a superior cytotoxic activities as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: August 27, 2002
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, Yun He, Sacha Ninkovic, Joaquin Pastor, Frank Roschangar, Francisco Sarabia, Hans Vallberg, Dionisios Vourloumis, Nicolas Winssinger, Zhen Yang, N. Paul King, M. Ray Finlay
  • Patent number: 6380394
    Abstract: Novel analogs of epothilone A, epothilone B, and epothilone C are synthesized by Stille coupling thazole-stannanes to macrolactone intermediates. The synthetic epothilone analogs selectively prevent mitosis in cancer cells through the induction and stabilization of microtubulin assembly. Selected synthetic epothilone analogs are demonstrated to have greater bioactivity than their corresponding native compound.
    Type: Grant
    Filed: June 22, 1998
    Date of Patent: April 30, 2002
    Assignee: The Scripps Research Institute
    Inventors: Kyriacos C. Nicolaou, N. Paul King, M. Ray Finlay, Yun He, Frank Roschangar, Dionisios Vourloumis, Hans Vallberg, Francisco Sarabia, Sacha Ninkovic, David Hepworth, Tianhu Li
  • Patent number: 6248742
    Abstract: Use of compounds of the formula I for preparing a medicated for protecting DNA in the initial phase and/or the prompting phase of carcinogenesis and for preventing oxidating stress in patients with diseases related to free radicals are described.
    Type: Grant
    Filed: June 24, 1997
    Date of Patent: June 19, 2001
    Inventors: Jan Bergman, Lennart Möller, Hans Vallberg